FDG PET
This article was originally published in The Gray Sheet
Executive Summary
Medicare Coverage Advisory Committee's Diagnostic Imaging Panel will hold a Jan. 10 meeting to discuss whether and when it is scientifically justified to use fluoro-D-glucose positron emission tomography or other neuro-imaging devices for the diagnosis and patient management of Alzheimer's disease, a Nov. 23 Federal Register notice announces. The meeting will focus on asymptomatic patients who are at high risk of AD due to positive family history, patients with mild cognitive impairment or similar syndrome and patients with dementia. The deadline for presentations and comments is Dec. 27...
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.